培美曲塞二线治疗晚期非小细胞肺癌的疗效观察

Therapeutic Efficacy Evaluation of Pemetrexed in the Second -line Treatment of Advanced Non-small Cell Lung Cancer

目的:探讨分析培美曲塞二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法:经病理学或细胞学确诊,一线化疗后出现复发或进展的晚期NSCLC患者56例,治疗方案为培美曲塞二钠500mg·m-2,从第1天给药,21 d为1个周期,完成2个周期以上化疗后评价疗效。结果:56例患者中,完全缓解(CR)0例,部分缓解(PR)4例,稳定(SD)32例,进展(PD)20例,有效率(RR)为7.1%(4/56),疾病控制率(DCR)为64.3%(36/58)。主要不良反应为骨髓抑制、皮疹、肝功能异常,经对症处理后不影响化疗进行。结论:培美曲塞二线治疗晚期NSCLC疗效较好,不良反应较轻,耐受性较好。

Objective： To analyze the clinical efficacy and adverse drug reactions of pemetrexed as the second-line treatment of advanced non-small cell lung cancer （NSCLC）. Methods： Confirmed by patho｜ogy or cytology, fifty-six patients with advanced recurrent or progressive NSCLC after first-line chemotherapy were enrolled and given pemetrexed 500 mg＇m-2 on the first day, one cycle of treatment was 3 weeks. The chemotherapy efficacy and adverse events were evaluated after 2 cycles. ResuLts： Among the 56 patients, there was no case of complete response, 4 cases of partial response, 32 cases of stable disease and 20 cases of progressive disease. The response rate （RR） was 7.1% （4/56） and the disease control rate （DCR） was 64.3% （36/58）. The common side effects were myelosuppression, rash and hepatic damage. Goriclusion： Pemetrexed has good efficacy and slight side effect in the second-line treatment of NSCLC.